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ABSTRACT
We have recently described an RNA-only gene regulation system for mammalian cells in which inhibition of self-cleavage of an
mRNA carrying ribozyme sequences provides the basis for control of gene expression. An important proof of principle for that
system was provided by demonstrating the ability of one specific small molecule inhibitor of RNA self-cleavage, toyocamycin, to
control gene expression in vitro and vivo. Here, we describe the development of the high-throughput screening (HTS) assay that
led to the identification of toyocamycin and other molecules capable of inhibiting RNA self-cleavage in mammalian cells. To
identify small molecules that can serve as inhibitors of ribozyme self-cleavage, we established a cell-based assay in which
expression of a luciferase (luc) reporter is controlled by ribozyme sequences, and screened 58,076 compounds for their ability
to induce luciferase expression. Fifteen compounds able to inhibit ribozyme self-cleavage in cells were identified through this
screen. The most potent of the inhibitors identified were toyocamycin and 5-fluorouridine (FUR), nucleoside analogs carrying
modifications of the 7-position and 5-position of the purine or pyrimidine bases. Individually, these two compounds were able
to induce gene expression of the ribozyme-controlled reporter ;365-fold and 110-fold, respectively. Studies of the mechanism
of action of the ribozyme inhibitors indicate that the compounds must be incorporated into RNA in order to inhibit RNA self-
cleavage.
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INTRODUCTION
The ability to ‘‘exogenously’’ control the expression of
genes in mammalian cells has been a powerful tool of
biomedical research (Gossen and Bujard 2002). Gene
regulation technology has already played a critical role in
efforts to understand the role of specific gene products
in fundamental biological processes, in development, and
in disease states. In the future, the technology offers the
opportunity to have a major impact in new areas of re-
search and medicine. To date, most commonly used gene
regulation systems rely on the control of transcription
(Gossen and Bujard 1992; Wang et al. 1994; Rivera et al.
1996; Suhr et al. 1998). More recently, the discovery of
RNA interference and siRNAs has led to the development
of novel strategies for controlling gene expression that rely
on the targeting of RNA (Fire et al. 1998; McManus and
Sharp 2002). In the hopes of extending the application and
utility of gene regulation technology, we have been inter-
ested in the development of new methods for controlling
gene expression that rely on the modulation of RNA self-
cleavage rather than transcription. The basis for such a
system is the incorporation of sequences encoding self-
cleaving RNA motifs (i.e., ribozyme sequences) into a
mammalian transcription unit, such that upon generation
of the resulting mRNA, spontaneous ribozyme self-cleavage
should lead to destruction of the mRNA and therefore
no gene expression. Administration of agents capable of
inhibiting RNA self-cleavage should result in preservation
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of the intact mRNA and therefore reinstate (i.e., ‘‘induce’’)
gene expression (Fig. 1A).
The two essential requirements of such an RNA-only
gene regulation system are the availability of ribozyme
sequences capable of efficient self-cleavage in mammalian
cells when embedded in an mRNA transcript, and the
availability of small molecules capable of inhibiting such
self-cleavage in mammalian cells. With regard to the first
requirement, we have recently tested a large number of
natural and synthetic ribozyme sequences for their ability
to function in mammalian cells when embedded in an
mRNA transcript. We were able to identify and further
develop a modified version of a hammerhead ribozyme,
derived from Schistosoma mansoni (Sm1), that is capable
of extremely efficient self-cleavage in mammalian cells
(Yen et al. 2004). This ribozyme, termed N79, was found to
function in a variety of commonly used mammalian cell
lines and in primary cells in vivo. An important proof of
principle for the use of inhibitors of RNA self-cleavage to
control gene expression was provided by the demonstration
of the ability of one specific small molecule inhibitor of
RNA self-cleavage, toyocamycin, to control gene expression
in vitro and vivo. Here, we describe the development of
the high-throughput screening (HTS) assay that led to the
identification of toyocamycin and other inhibitors of RNA
self-cleavage. Rather than rely on in vitro screens of
compounds, we chose to develop a mammalian cell-based
screen in order to directly identify molecules capable of
functioning within cells. Since a variety of aminoglycoside
(Stage et al. 1995; Murray and Arnold 1996; Hermann and
Westhof 1998; Tor et al. 1998; Jenne et al. 2001) and non-
aminoglycoside antibiotics (Jenne et al. 2001) had been
previously shown to be able to inhibit the self-cleavage of
hammerhead ribozymes in the in vitro setting, we first
screened such compounds in the cell-based assay. We then
extended the studies to include the high-throughput
screening of 58,076 compounds. We report here the results
of those screening efforts and the characteristics (and in
some cases, the mechanism of action) of the inhibitors that
were identified.
RESULTS
Generation of reporter cell lines for
cell-based screening
For screening purposes, we chose to generate a stable
human (HEK-derived) cell line that carries an integrated
mammalian expression vector in which a luc reporter
gene’s expression is placed under the control of the CMV
promoter and with two copies of the N79 ribozyme (Fig.
1B). Stable cell lines were generated by cotransfection of
HEK 293 cells with the reporter construct, an expression
FIGURE 1. Strategy for identifying new ribozyme inhibitors via high-throughput screening. (A) Controlling gene expression via the modulation
of RNA self-cleavage. When a cis-acting hammerhead ribozyme is embedded in the mRNA, self-cleavage leads to the destruction of the mRNA
and results in the absence of gene expression. However, the administration of specific inhibitors of the ribozyme leads to the generation of intact
mRNAs and results in protein expression. (B) Schematic representation of the N79 ribozymes and the reporter gene expression vector used for the
cell-based screening assay. Stable cell clones that had low background luc expression and could be induced by morpholino anti-sense
oligonucleotides as shown in the bioluminescent images were selected for the use in the screen. The black line identifies the sequence targeted by
the anti-sense oligonucleotide. Nucleotide numbering follows standard nomenclature (Hertel et al. 1992).
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vector encoding puromycin resistance, and subsequent
selection in puromycin-containing medium. Approximately
10 clonal cell lines were generated in this way. To identify
specific cell lines capable of responding to putative inhib-
itory molecules, all cell lines were tested for both their basal
level of luc expression and for the extent of induction of luc
expression achieved after transfection of the cells with an
anti-sense morpholino oligonucleotide known to block the
cleavage of N79 (Yen et al. 2004). Several cell lines tested in
this way expressed very low basal levels of luc, yet were
readily induced to express luc after administration of oligo-
nucleotide. One of these cell lines, termed HEK79, showed
a 20-fold induction of luc expression after oligonucleo-
tide administration and was chosen for high-throughput
screening (Fig. 1B).
High-throughput screening of compound libraries
As indicated above, several different antibiotic compounds
have been previously shown to inhibit ribozyme activity in
vitro. As a first step toward the identification of com-
pounds capable of inhibiting ribozyme cleavage in mam-
malian cells, we tested a variety of such compounds (Table 1),
using both the HEK79 cell line and cells transiently trans-
fected with different N79 variants. None of the compounds
tested revealed an appreciable inhibitory effect on ribozyme
self-cleavage, when administered at concentrations of either
10 or 100 mM (data not shown).
Based on those results, we extended the screening effort
to include 58,076 compounds. The full set of compounds
included an annotated bioactive compound library (2036
compounds) (Root et al. 2003); a diversity library obtained
from NINDS (1040 compounds) (Lunn et al. 2004); a col-
lection of FDA-approved drugs (1000 compounds) (Rogers
et al. 2002); a combinatorial library from Comgenex
(20,000 compounds); a library containing both natural
products and synthetic compounds (TIC; 24,000 com-
pounds) (Kelley et al. 2004); and a combinatorial library
called the ‘‘World Diversity Set,’’ obtained from Specs,
containing compounds chosen for geographic as well as
chemical diversity (10,000 compounds). For this high-
throughput screening effort, the HEK79 cells were seeded
in a 386-well format and exposed to the different com-
pounds at a final concentration of 4 mg/mL for 48 h, and
luc activity was then measured using a plate reader.
Molecules were considered positive if they induced luc
expression in cells carrying functional N79 ribozymes but
not in cells carrying inactive N79 ribozymes. Through this
primary screening effort and subsequent analysis of similar
analogs of positive molecules, 15 ribozyme inhibitors were
identified. The maximal fold increase in luc expression
achieved by each compound (Foldmax) and the concen-
tration that yields 50% of maximal induction (EC50) are
summarized in Table 2. All of the identified molecules were
shown to possess comparable activity in a separately
generated N79-carrying cell line to that observed in the
HEK79 cell line used for the original screening (data not
shown). Interestingly, none of the inhibitors that were
identified were aminoglycosides, despite the presence of
many such molecules in the libraries.
Characterization of positive compounds
Based on structural similarities, the identified molecules
can be divided into three groups. The first group consists of
adenosine analogs, including tubercidin (7-deaza-adenosine),
tubercidin-monophosphate and -triphosphate, tubercidin-
cyclic monophosphate, sangivamycin, 8-azaadenosine, tri-
cyclic nucleoside, and toyocamycin. All members of this
group contain at least a modified 7-position on the purine
(Fig. 2A). Analogs that have modifications other than at
the 7-position, such as 2-amino, 3-deaza, 6-chloro, 9-deaza,
lacked an inhibitory effect. In addition, the identified com-
pounds all contain a 29OH group on the sugar base,
indicating that a ribose is necessary for their inhibitory
effects (Fig. 2A). Similar analogs that lack 29OH or are
missing the ribose entirely produced no appreciable inhibition
(29-deoxy-tubercidin, 29-deoxy-toyocamycin) (Fig. 2B). Of
all the compounds, toyocamycin (Aszalos et al. 1966) was
found to be the most potent ribozyme inhibitor, resulting
in up to 365-fold luc induction when applied to the stable
cell line. The effectiveness of the remaining compounds in
this group was <60-fold (Table 2). Based on its apparent
higher effectiveness, a dose-response curve of toyocamycin
on the stable cell line was generated. As shown in Figure
2C, the induction peaked rapidly around 1 mM and then
dropped off sharply. This drop coincided with apparent cell
toxicity observed by microscopy. In addition, a decrease of
luc expression from cells carrying inactive ribozymes,
presumably due to the toxicity effects of the compound,
was observed when the concentration of toyocamycin
reached 0.5 mM. The dose-limiting toxicity of toyocamycin
thus excludes its use at higher concentration or for long-
term applications.
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The second group of ribozyme inhibitors identified in the
screen consists of uridine analogs, including 5-bromouridine,
5-fluorouridine (FUR), and 5-fluorouracil (5FU) (Fig. 3A).
All contain a 5-position modification on the pyrimidine.
Analogs that contain an iodo, a methyl, a hydroxyl, an
ethyl, or an aza group on the 5-position lack an inhibitory
effect. In the case of this group of inhibitors, FUR was the
most potent. However, replacing the 29OH group of FUR
by either 29deoxy or 29O-methyl, or by inverting the stereo-
center of the 29-position (Fig. 3B), resulted in loss of inhi-
bition, indicating that, as with adenosine analogs, a ribose
is necessary for the inhibitory effects of uridine analogs. In
contrast to toyocamycin, the dose-response curve of FUR
reached a plateau of 110-fold at 50 mM, and the plateau was
maintained for a wide range of concentrations (Fig. 3C),
suggesting that an efficient induction can be reached with
a lower dosage before reaching severe toxicity. The related
molecule 5FU (Longley et al. 2003), however, has a dose-
response curve resembling that of toyocamycin, reaching
a peak of 65-fold followed by a quick drop-off (Fig. 3D).
The effectiveness of 5FU was also significantly less, re-
quiring a concentration of 500 mM to reach 50% of the
maximal induction, as compared to the 6 mM required for
FUR (see EC50 in Table 2). For both FUR and 5FU, a
decrease of luc expression from cells carrying inactive
ribozymes was observed when concentrations reached 800
mM.
The third group of ribozyme inhibitors belongs to the
family of RNA-binding dyes, and includes Syto-83, ethid-
ium bromide (homidium bromide), and acridine orange
(Fig. 4A). These dyes were also far less potent inhibitors
than the adenosine or uridine analogs (Table 2).
As mentioned earlier, the N79 ribozyme used in our cell-
based assay was developed from Sm1 of S. mansoni
(Ferbeyre et al. 1998), a human parasite
that infects people in many areas of the
world (Ross et al. 2002). It is intriguing
that one of the drugs suggested in the
past as potential treatments for Schisto-
some infection was tubercidin (Jaffe
et al. 1971; el Kouni 1991), the same
molecule identified in our screen as an
Sm1 ribozyme inhibitor. This prompted
us to test other molecules with known
anti-Schistosomal effects for their
inhibitory potential. These included
nebularine, dipyridamole, benzylacy-
clouridine, metrifonate, oxamniquine,
praziquantel, and artemether. However,
only nebularine (also an adenosine an-
alog) (el Kouni and Cha 1987) showed
an inhibitory effect on ribozyme self-
cleavage, albeit minimal (Table 2). In-
terestingly, unlike most of the adeno-
sine analogs found in our screen,
nebularine contains a modification on the 6- but not the
7-position of the purine base (Fig. 2A).
Lastly, it should be noted that while there were numerous
guanosine and cytidine analogs in the 58,076 compounds
screened, none of them surfaced as ribozyme inhibitors. In
particular, 7-deazaguanine and 7-deazaguanosine triphos-
phate (the purine counterparts of tubercidin) and 5F-
cytosine (the pyrimidine counterpart of 5FU) (Fig. 4B) all
showed no inhibitory effects when tested at similar concen-
trations that produced inhibition by adenosine analogs or
uridine analogs. The fact that only adenosine and uridine
analogs but no guanosine and cytidine analogs were found
positive may provide an insight into the N79 structure–
function relationship (see below).
Mechanisms responsible for ribozyme inhibition:
RNA incorporation vs. RNA binding
To examine the mechanisms responsible for ribozyme inhibi-
tion, we incubated the N79 ribozyme with either tubercidin
or toyocamycin in an in vitro catalytic reaction. Surpris-
ingly, neither tubercidin (Fig. 5A, lanes 3–8) nor toyocamycin
(Fig. 5B, lanes 3–8) was able to inhibit ribozyme self-cleavage
in vitro, as indicated by the unaltered cleavage percentage
over a broad range of compound concentrations. The lack
of direct inhibition by these molecules indicated that their
mechanism of inhibition was not likely due to direct
ribozyme–compound interactions. In light of our findings
that inhibitory activity appeared to always be associated
with a 29OH group on the sugar base, we next asked
whether covalent incorporation of these analogs into the
ribozyme-containing RNA might be required for the in-
hibition of RNA self-cleavage. To test if covalent incorpo-
ration of identified inhibitory molecules can, indeed, lead
TABLE 2. Compounds found to inhibit ribozyme activity in cells
Compound name EC50 (mM)
a Foldmax
b Class
Toyocamycin 0.4 378.2 Adenosine analog
8-Azaadenosine 3.6 45.4 Adenosine analog
Sangivamycin 1.1 38.2 Adenosine analog
Tubercidin 2.5 57.8 Adenosine analog
Tubercidin-cyclic monophosphate 34.4 35.1 Adenosine analog
Tubercidin-monophosphate 2.2 39.3 Adenosine analog
Tubercidin-triphosphate 1.9 34.7 Adenosine analog
Nebularine 10.2 8.4 Adenosine analog
Tricyclic nucleoside 39.5 12.0 Adenosine analog
5-Fluoro-uridine 5.9 120.9 Uridine analog
5-Bromo-uridine 266.6 15.5 Uridine analog
5-Fluoro-uracil 499.5 65.3 Uridine analog
Syto-83 7.4 25.6 RNA-binding dye
Homidium bromide 2.3 8.4 RNA-binding dye
Acridine orange 7.0 3.6 RNA-binding dye
aThe effective concentration at 50% of maximal induction.
bNumbers are maximal ‘‘fold increase’’ in luciferase expression after 24 h of compound
treatment.
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to cleavage inhibition, tubercidin-triphosphate was used in
place of ATP in an in vitro transcription reaction to
generate ribozyme RNA carrying substitutions in all aden-
osine positions. As shown in Figure 5C, this substitution
resulted in the complete loss of ribozyme self-cleavage (Fig.
5C, lanes 2–6), while the unsubstituted ribozyme cleaved
efficiently under the same conditions (Fig. 5C, lane 7).
Similarly, FUR (Fig. 5D) and 5FU (Fig. 5E) exhibited no
inhibitory effect when incubated directly with N79 ribozyme
at concentrations that would normally produce pro-
nounced induction in the cell-based assays. Our attempts
to examine the effect of incorporating FUR into the N79
ribozyme were inconclusive due to the difficulty of gener-
ating full-length FUR-substituted N79 ribozyme by T7
polymerase. However, past studies using chemical synthesis
to generate FUR-containing hammerhead ribozymes dem-
onstrated that when incorporated at certain key positions
of the ribozyme, FUR, indeed, impaired self-cleavage
(Hammann et al. 2001).
FIGURE 2. Chemical structures of identified adenosine analog
ribozyme inhibitors and related compounds. (A) Analogs capable of
inhibiting ribozyme self-cleavage in cells contain at least a modified
7-position on the purine, with the exception of nebularine, which
contains a 6-position modification. These compounds all have a 29OH
group on the sugar base. The differences between these compounds
and the inactive adenosine are indicated by the yellow shade. (B)
Examples of analogs that lacked an inhibitory effect. (C) Dose-
response curve of toyocamycin in log scale. Error bars indicate
1 S.D. (standard deviation).
FIGURE 3. Chemical structures of identified uridine analog ribo-
zyme inhibitors and related compounds. (A) Analogs capable of
inhibiting ribozyme self-cleavage in cells contain a modified 5-
position on the pyrimidine. These compounds all have a 29OH group
on the sugar base. The differences between these compounds and the
inactive uridine are indicated by the yellow shade. (B) Examples of
analogs that lacked the inhibitory effect. (C) Dose-response curve of
FUR in log scale. (D) Dose-response curve of 5FU in log scale. Error
bars indicate 1 S.D.
Inhibitors of ribozyme self-cleavage in mammalian cells
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Consistent with the mechanism of covalent incorpora-
tion of the compounds into the ribozyme-encoding cellular
mRNA, it has been reported that tubercidin (Acs et al.
1964), toyocamycin (Suhadolnik et al. 1967), 5-FUridine
(Glazer and Lloyd 1982), and 5-FU (Glazer and Lloyd 1982)
are able to enter the ribonucleotide pool for RNA synthesis
and can be found in the cellular RNAs of mammalian cells.
This mechanism of inhibition of ribozyme function, de-
pendent on inhibitor incorporation into RNA, may shed
light on the basis for our identification of only adenosine
analogs with a modified 7-position and uridine analogs
with a modified 5-position as effective inhibitors and our
inability to identify any analogous guanosine and cytidine
analogs. While these findings might simply relate to the
variable cell permeability of different molecules, or their
ability to be recognized by RNA polymerases for incorpo-
ration, they may suggest that structural interactions invol-
ving the 7- and 5-positions of A and U bases, respectively,
are particularly important for N79 ribozyme function in
vivo. Although the 7-position of A does not form hydrogen
bonds in the standard Watson-Crick base pairs, the X-ray
structures of hammerhead ribozymes, indeed, showed its
involvement in forming the nonstandard A-G base pairs
in the conserved core (A9-G12, A13-G8; see Fig. 2 for the
nucleotide numbering) (Fu and McLaughlin 1992; Pley
et al. 1994; Scott et al. 1995). The role of the 5-position of
U is less clear since it is not involved in hydrogen bonds of
either the standard Watson-Crick or the G-U wobble base
pairs. Nevertheless, it was shown that incorporating FUR
at the U4 and U7 of the hammerhead core led to the
impairment of self-cleavage (Hammann et al. 2001). Thus,
modifying those A and U bases in the conserved core could
lead to the graded loss of cleavage activity in vivo.
Furthermore, the N79 ribozyme contains an unusually
high percentage of A and U bases in its loops I and II.
Substituting these bases could disrupt the critical interac-
tion of the two loops required for the ribozyme to function
in cells (De la Pena et al. 2003; Khvorova et al. 2003;
Penedo et al. 2004; Yen et al. 2004).
Synergistic inhibition of ribozyme function by
combined administration of toyocamycin and FUR
As toyocamycin (an adenosine analog) and FUR (a uridine
analog) would occupy different positions if they were in-
corporated into the N79 ribozyme, we next asked whether
combined administration of the two compounds might
lead to improved inhibition of ribozyme function relative
to addition of a single compound and perhaps define a less
toxic regimen for achieving reasonable levels of induction of
gene expression. To address this question, varying amounts
of each compound were combined and added to HEK79
cells, and subsequently, the fold induction of luc expression
was determined. As shown in Figure 6, administration of
specific concentrations of the two compounds did, indeed,
result in a more efficient inhibition of the ribozyme than
was possible with either compound alone (e.g., 670-fold
induction by a combination of the two compounds vs.
120-fold induction by FUR alone or 378-fold induction by
toyocamycin alone). In addition, a variety of mixtures of
the two compounds were able to induce gene expression
between 200- and 600-fold (Fig. 6), in contrast to the nar-
row range of concentrations of toyocamycin for which
induction can be achieved in the absence of significant
toxicity (Fig. 2C). To document the practical use of this
two-compound cocktail for the regulation of gene expres-
sion in vivo, we established an in vivo model in which an
AAV vector encoding a luc reporter controlled by two
copies of the N79 ribozyme (similar transcription cassette
to that diagrammed in Fig. 1) was injected subcutaneously
to the left ear of nude mice. To provide an internal control,
all mice were also injected in the right ear with virus
carrying the inactive N79. After 3 wk, these mice were
imaged for basal luc gene expression (day 0), and imme-
diately after imaging, a single pulse of cocktail was of mice,
taken before and 2–3 d after cocktail injection, are shown
in Figure 7. The images demonstrate that, as expected, the
right ear carrying the inactive N79 showed little change
in gene expression before and after cocktail treatment.
In contrast, in the left ear carrying the functional N79,
a pronounced induction was readily detectable after the
treatment. Quantification of the photon output indicated
that the induced gene expression reached 37-, 17-, and 13-
fold in the three mice treated. The induction afforded by
this single pulse injection method was somewhat variable
from mouse to mouse, most likely due to the variability of
cocktail volume delivered.
FIGURE 4. Chemical structures of identified RNA-binding dye
ribozyme inhibitors and several guanine and cytidine analogs related
to tubercidin and 5FU that lack inhibitory activity. (A) RNA-binding
dyes. The structure of Syto-83 is currently unavailable. (B) Structure
of guanosine and cytidine analogs with similar functional groups to
that of tubercidin and 5FU but that lacked the inhibitory activity.
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DISCUSSION
The work described here represents the first cell-based
screen aimed at identifying small molecules capable of
modulating ribozyme self-cleavage in vivo. By screening
58,076 compounds, we were able to identify two small
molecules, toyocamycin and FUR, that can potently inhibit
ribozyme function in mammalian cells. It is of significant
interest that the two most potent inhibitors of ribozyme
function in cells that we identified appear to inhibit ribozyme
self-cleavage via their covalent incorporation into the
mRNA carrying the ribozyme sequences, as evidenced by
the inability of these molecules to inhibit ribozyme self-
cleavage in vitro and by the loss of self-cleavage activity
when these molecules are incorporated. Based on the well-
described interactions between specific aminoglycosides
and other small molecules and RNA (Stage et al. 1995;
Murray and Arnold 1996; Hermann and Westhof 1998;
Tor et al. 1998; Jenne et al. 2001), we had expected that our
extensive screen of compounds would have led to the
identification of compounds that inhibit ribozyme self-
cleavage by virtue of their direct binding to ribozyme-
containing RNA. Our inability to identify such compounds
may suggest that the complex structure of mRNA mole-
cules and their associated proteins present in mammalian
cells greatly restricts the possibilities for the types of
interactions between small molecules and RNAs that can
lead to the inhibition of RNA self-cleavage. The ability of
morpholino oligonucleotides and several RNA-binding
dyes to inhibit ribozyme activity in cells, however, suggests
that appropriate interactions between specific small mole-
cules and ribozymes that lead to inhibition of self-cleavage
in vivo are indeed possible. We are hopeful that additional
screening efforts will lead to the identification of new in-
hibitors of ribozyme function with improved toxicity
profiles and more desirable pharmacokinetic properties.
We had already made use of one of the molecules
identified in the current study, toyocamycin, to provide
a critical ‘‘proof of principle’’ for the ability to regulate gene
expression in mammalian cells both in vitro and in vivo via
the modulation of RNA self-cleavage (Yen et al. 2004). As
expected by the proposed mode of action of this inhibitor,
we showed in that study that in the absence of toyocamy-
cin, the ribozyme-controlled mRNA was not detectable in
the nucleus or cytoplasm in cells carrying active ribozymes,
consistent with the mechanism that ribozyme self-cleavage
leads to rapid degradation of mRNAs. However, when these
cells were treated with toyocamycin, the amount of luc
mRNA increased to a level comparable to that of cells
carrying inactive ribozyme, which is consistent with the
mechanism that inhibition of ribozyme self-cleavage leads
to the generation of intact mRNA in cells (Yen et al. 2004).
In the present studies, we show that the combined ad-
ministration of toyocamycin and FUR to cells harboring
a ribozyme-regulatable expression construct leads to an
improved induction of gene expression, relative to the use
of toyocamycin alone. This combined regimen requires
lower concentrations of the two compounds than must be
used to achieve reasonable levels of inductions using either
compound alone, and consequently results in a less toxic
effect on the cells. While it is hopeful that the use of such
a two-compound cocktail may enable more experimental
applications of the ribozyme-based gene regulation system
than are possible with toyocamycin alone, the identification
FIGURE 6. Combined administration of toyocamycin and FUR leads
to improved levels of induction of gene expression. The numbers next to
each contour line represent ‘‘fold increase’’ in gene expression induced
by 24 h of cocktail treatment. The concentrations are in log scale.
FIGURE 7. Control of gene expression in vivo after coadministration
of toyocamycin and FUR. About 5 mL of recombinant AAV carrying
the active N79/luc transgene (titer of 1012 genome copies/mL), or
recombinant AAV carrying the inactive N79/luc transgene (titer of
53 109 genome copies/mL) were injected into the left or the right ear,
respectively. Three weeks later, a single pulse of roughly 5 mL of
cocktail containing 20 mM of toyocamycin and 12 mM of FUR was
injected in each ear (day 0). Animals were imaged as previously
described (Yen et al. 2004) to determine the levels of luc expression
prior to the addition of compounds, and 2 d after compound
treatment. The figure shows a representative animal of the three-
animal cohort. The induction in fold described in text was calculated
based on the photon output in the left ear before and after cocktail
treatment, and was normalized to the photon output from the right
ear.
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of significantly less toxic inhibitors of ribozyme function
remains an important goal of future research.
In addition to the use of the ribozyme-based gene
regulation system for the control of expression of gene prod-
ucts, the finding that one of the most commonly used
chemotherapeutic agents, 5FU, can serve as a ribozyme
inhibitor in vivo raises the interesting possibility that one
novel application of RNA-only gene regulation systems
might relate to the real-time ‘‘sensing’’ of the presence of
specific compounds in vivo. In the specific case of 5FU,
the ability of the molecule to induce expression of a reporter
gene could provide an important means of monitoring 5FU
uptake and retention by tumors and normal tissues, and/or
facilitate efforts to develop more optimal routes of 5FU
administration.
MATERIALS AND METHODS
High-throughput screening of compound libraries
ACL, NINDS, TIC, and Comgenex libraries were collected by
Dr. Brent Stockwell, prepared as 4 mg/mL solutions in DMSO,
and screened at a final concentration of 4 mg/mL. FDA2000 was
collected by Dr. Steve Gullans (BWH), and each compound was
prepared at 10 mM in DMSO and screened at 10 mM. The Specs
library was prepared as 10 mg/mL and screened at 10 mg/mL.
HEK79 cells were seeded in white, opaque-bottom 386-well
plates at a density of 8000 cells per well in medium with 10%
serum and pen/strep using the Zymark dispenser. On the same
day, cells were treated with compounds at a final concentration of
4 mg/mL and 0.1% DMSO, followed by an incubation period of
48 h at 37°C in a humidified incubator containing 5% CO2. Cells
were then lysed, and luciferin was added to the cells at a final
concentration of 4 mg/mL; the amount of light output from each
well was recorded on a Packer Fusion platereader. Induction of luc
expression by a particular compound was calculated by subtract-
ing the signal with instrument background and background from
untreated cells. All screens were performed in triplicate repeats.
Cell culture assays for testing the effective
concentration of compounds
Plasmid DNAs carrying a LacZ reporter under the control of two
copies of the N79 ribozyme were transfected into subconfluent
HEK293T cells using Fugene6 (Roche). The next day, cells were
treated with compounds at various concentrations for 24 h. The
level of b-galactosidase expression was then quantified by ONPG
assay 24 h later. All experiments were performed at least in trip-
licate. Alternatively, HEK79 cells (stable cell lines containing a luc
reporter under the control of two copies of N79 ribozymes; see
Results) were seeded in white, opaque-bottom 96-well plates with
a density of 40,000 cells per well, and treated with compounds the
next day at various concentrations for 24 h. Luciferin was then
added to the cells at a final concentration of 20 mg/mL, and the
amount of light output from each well was recorded on a plate
reader. All experiments were performed at least in triplicate. 5FU
(from Sigma) was prepared as 100 mM stock in 100% DMSO;
FUR (Sigma), as 10 mM stock in PBS; toyocamycin (Berry &
Associates) and tubercidin (Sigma), as 10 mM stock in 10%
DMSO.
In vitro transcription and catalytic reaction
DNA templates containing a T7 promoter and the ribozyme
sequences were generated by PCR. 33P-labeled RNA was then
transcribed by T7 RNA polymerase in the presence of 50 mM
blocking anti-sense oligonucleotides using Ambion’s MEGAshort-
script kit. The anti-sense oligonucleotide sequence used was
59-GATAGCAGTGGAATCCAGGACGCAC-39. In the absence of
the anti-sense oligonucleotide, z95% of the transcripts were
cleaved during the 3-h in vitro transcription reactions. In the pres-
ence of the anti-sense oligonucleotide, the percentage of cleavage
products dropped to 35%. To make ribozymes with incorporated
tubercidin, transcription was carried out by substituting ATP with
tubercidin triphosphate. Full-length RNAs were then purified by
10% denaturing polyacrylamide gel. To determine the cleavage
efficiency, ribozyme was incubated in 50 mM Tris-HCl (pH 7.5)
for 3 min at 95°C and slowly cooled to 23°C in 15 min. Self-
cleavage reactions in the presence or the absence of inhibitory
compounds were triggered by adding MgCl2 to 1 mM or 10 mM
at 23°C. The reaction was stopped by adding 5 volumes of stop
solution (8 M urea, 50% formamide, 40 mM EDTA), and the
cleaved fragments were separated by a 10% denaturing poly-
acrylamide gel. Cleavage percentage was then quantified by
PhosphorImager. We did not detect any cleavage products in
transcription reactions when tubercidin triphosphate was used to
replace ATP.
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